How have the shares performed?
Petros Pharmaceuticals Inc. (PTPI) saw an uptrend of 5.74% in the recent trading with $3.13 being its most recent. The current price level -47.48% lower than the highest price of $5.96 marked by the stock while trading over the past 52-weeks, whereas it is 73.89% higher than the lowest price of $1.80 the company dropped to over past 52-weeks. The latest news story on PTPI appeared in PR Newswire under the title “Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales” on May-17-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -29.66% below one month high and is +9.06% above of the lowest during that time. Looking into the simple moving average, Petros Pharmaceuticals Inc. (PTPI)’s stock stands at a SMA-50 of $3.28 while that of 5-day is reading $3.08.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
Petros Pharmaceuticals Inc. Earnings – What Happened With PTPI
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $3.46 billion.
PTPI – Petros Pharmaceuticals Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 9.73 million. PTPI does have institutional investors; and they hold 8.20% of the stock.
Petros Pharmaceuticals Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, PTPI declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Dec 30, 2020, NorthRock Partners, LLC was the top most holder in Petros Pharmaceuticals Inc. (NASDAQ:PTPI) with an ownership of 0.39 million shares of the company or 3.94% of the stake worth $1.69 million. The filing also reveals Renaissance Technologies, LLC as the second largest holder in the company with a control over 1.47% of the outstanding shares. Its stake is worth $0.63 million for having 0.14 million shares in hand.
Acorn Financial Advisory Services Inc. also came holding a key position in the company during the recent quarter and it now holds 0.64% of the outstanding shares. With this there are now 21 institutions which have possession in PTPI’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. The count was 3.04 for long-term debt to equity ratio.
Technical Analysis of Petros Pharmaceuticals Inc. (NASDAQ:PTPI) stock